- Matrix Pharma Corp has inaugurated a new oncology manufacturing facility, Unit-8, in Vizag, India, dedicated to high-potency active pharmaceutical ingredient (HPAPI) production.
- The 10,000 sq. ft. facility supports containment below 1 μg/m³ and flexible batch scale-up ranging from 10–50 kg.
Matrix Pharma Corp has inaugurated a new oncology manufacturing facility, Unit-8, in Vizag, India. The facility is designed to support the production of highly potent active pharmaceutical ingredients (HPAPIs) for oncology applications and strengthens the company’s manufacturing infrastructure for high-potency compounds.
The new facility includes a 10,000 square foot HPAPI production block with containment capability below 1 μg/m³. According to the company, the site is designed to support the handling of highly potent molecules while meeting global regulatory compliance requirements for pharmaceutical manufacturing.
The facility features glass-lined and stainless steel reactors ranging from 100 to 1,600 litres, isolator-integrated processing systems, and filtration and drying systems built with Hastelloy and stainless steel. Additional infrastructure includes a dedicated quality control isolator train, storage for key starting materials and finished goods, and dedicated powder processing and packing areas.
The oncology unit has been designed to support flexible scale-up with batch sizes ranging from 10 to 50 kilograms. Matrix Pharma Corp stated that the infrastructure is intended to support safe handling, precision processing, and operational efficiency for high-potency oncology compounds within its manufacturing operations.
